Executive Management

R. Scott Struthers, Ph.D., is Co-founder and Chief Executive Officer of Crinetics. He has served on the company’s board of directors and as President since starting the company in 2008.  

Prior to Crinetics, he was Senior Director and Head of Endocrinology and Metabolism at Neurocrine Biosciences, Inc. At Neurocrine, Scott initiated and led the company’s efforts to discover and develop orally active, nonpeptide gonadotropin-releasing hormone antagonists, including elagolix. Prior to Neurocrine, he co-founded ScienceMedia Inc. to develop e-learning solutions for the life sciences and higher education markets, and led contract research efforts at Biosym Technologies to develop and apply computational tools for drug discovery. In 2009, Scott co-founded the nonprofit San Diego Entrepreneurs Exchange, where he continues to serve on the board of directors. 

Since October 2021, Scott has served as chair of the board of directors at Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for oncology indications, in which Crinetics holds a minority equity stake.  

Scott holds a doctorate in physiology and pharmacology from the University of California, San Diego, based on the work he performed at the Salk Institute for Biological Studies.